A Collaborative Online AI Engine for CT-Based COVID-19 Diagnosis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clinical Characteristics and Risk Factors for Developed COVID-19 Patients Transferring to Designated Hospital from Jianghan Fang
medRxiv preprint doi: https://doi.org/10.1101/2020.04.21.20074724; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: a retrospective, observational study 1Yunfei Liao#, 2Yong Feng #, 3Bo Wang#, 1Hanyu Wang, 4Jinsha Huang, 5Yaxin Wu, 1Ziling Wu, 1Xiao Chen, 6Chao Yang, 7Xinqiao Fu and 1Hui Sun 1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Liao MD PhD, H Wang MD, Z Wu MD, X Chen MD, H Sun MD); 2Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Feng MD PhD); 3Department of Rehabilitation, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (B Wang MD); 4Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (J Huang MD PhD); 5First Clinical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China (Y Wu BD) 6Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (C Yang MD PhD); 7Outpatient Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (X Fu PhD) # Contributed equally Correspondence to Hui Sun MD, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
Vaccines Currently in Development
COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES Begin Phase 1 trials in late TAK-888, antibodies from PhRMA spring. To patients between 1 recovered COVID-19 N/A Takeda Pre-clinical Wall Street Journal December 2020 and December patients Pink Sheet 2021 Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Antibodies from recovered Korea Herald 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 COVID-19 patients UPI Antibodies from recovered BioSpace 4 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 5 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech Antibodies from recovered Lilly/Ab-Cellera (NIH Vaccines 6 N/A Pre-clinical Start Phase 1 in late July 2020 Endpoints News COVID-19 patients Research Center) * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources. It is not an endorsement Copyright 2020 Updated April 2, 2020, at 2:30 p.m. -
A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab- Based Treatment F
www.nature.com/scientificreports OPEN Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab- based treatment F. Du, P. Yuan, Z. T. Zhao, Z. Yang, T. Wang, J. D. Zhao, Y. Luo, F. Ma, J. Y. Wang, Y. Fan, R. G. Cai, P. Zhang, Q. Li, Y. M. Song & B. H. Xu Scientific Reports 6:33825; doi: 10.1038/srep33825; published online 21 September 2016; updated on 14 October 2016 The Acknowledgements section in the PDF version of this Article is incorrect. “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C0466), and funded by the Ministry of Health & Welfare, Republic of Korea (HI14C3344)”. should read: “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This work was supported by Beijing Hope Run Special Fund (LC2013L09) and Capital Clinical Feature Applied Research Fund (Z141107002514010). -
Care of Pediatric Patients During COVID-19 Pandemic
Care of Pediatric Patients during COVID-19 Pandemic Wuhan United “Living Through A Pandemic” Series 4 Co-organized with: Department of Pediatrics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Forti & Consevage, P.C., Pennsylvania, USA Mead Johnson Nutrition, USA MEDICAL DISCLAIMER THIS PRESENTATION IS FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND MAY NOT BE CONSTRUED AS MEDICAL ADVICE. THE INFORMATION IS NOT INTENDED TO REPLACE MEDICAL ADVICE OFFERED BY PHYSICIANS. Contents 1. Opening remarks: Dr. Runming Jin 2. Diagnosis, Treatment and Prevention of COVID-19 in Children: Dr. Xiaoyan Wu 3. Management of Wards of Pediatric Hematological-Malignancy during COVID-19: Dr. Xiaoyan Wu 4. Protection for Medical Staff: Dr. Lei Li 5. Management of Children with other Non-COVID 19 related Health Care Needs: Dr. Lei Li Opening Remarks Runming Jin Clinical Professor, Department Chair Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Diagnosis, Treatment and Prevention of COVID-19 in Children Xiaoyan Wu MD, PhD, Associate Professor Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Information of Pediatric Patients in China • 2143 pediatric patients with COVID-19 were reported to the Chinese Center for Disease Control and Prevention from January 16 to February 8, 2020 • 731 (34.1%) laboratory-confirmed cases and 1412 (65.9%) suspected cases. • 1213 cases (56.6%) were boys. The age of disease onset ranged from 1.5m to 17y. • The median time from illness onset to diagnoses was 2 days (range: 0 to 42 days). • Of the 2143 pediatric patients, only one child died. -
Curriculum Vitae Huiyun Xiang, M.D
Curriculum Vitae Huiyun Xiang, M.D., M.P.H., Ph.D. Professional Address Home Address Center for Injury Research and Policy 4506 Bradford Road The Research Institute at Nationwide Children’s Hospital Upper Arlington, OH 43220 700 Children’s Drive Phone: (614) 459-8248 Columbus, OH 43205 Phone: (614) 355-2768 Fax: (614) 722-2448 Email: [email protected] Academic Education 1999 Ph.D. College of Veterinary Medicine and Biomedical Sciences Colorado State University Major: Injury Epidemiology 1991 M.P.H. School of Public Health Tongji Medical College Major: Health Statistics 1988 M.D. Tongji Medical College Major: Preventive Medicine Special Training 2006-2007 Upper Arlington Leadership Program City of Upper Arlington, Columbus, Ohio 2001-2002 Advanced Public Health Leadership Fellow Regional Institute for Health & Environmental Leadership Denver University 2000 Colorado Advanced Supervisory Leadership Training Colorado State Department of Personnel and Administration 1999 Colorado Supervisory Leadership Training Colorado State Department of Personnel and Administration Professional Employment Huiyun Xiang, MD MPH PhD - 2 - 2009-Present Associate Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s Hospital Department of Pediatrics College of Medicine The Ohio State University 2003- 2008 Assistant Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s -
(TJDBPS01): Study Protocol for a Multicenter Randomized Controlled Trial
Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01): study protocol for a multicenter randomized controlled trial. Hang Zhang1, Junfang Zhao1, Yechen Feng1, Rufu Chen2, Xuemin Chen3, Wei Cheng4, Dewei Li5, Jingdong Li6, Xiaobing Huang7, Heguang Huang13, Deyu Li14, Jing Li7, Jianhua Liu8, Jun Liu9, Yahui Liu10, Zhijian Tan11, Xinmin Yin4, Wenxing Zhao12, Yahong Yu1, Min Wang1✉, Renyi Qin1 ✉. Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare. 1 Department of Biliary–Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. 2 Department of Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 3 Department of Pancreaticobiliary Surgery, The Third Affiliated Hospital of Soochow University, Jiangsu 213000, China. 4 Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, China. 5 Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 404100, China. 6 Department of Pancreatico-Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China. 7 Department of Pancreatico-Hepatobiliary Surgery, The Second Affiliated Hospital, Army Medical University, PLA, Chongqing 404100, China. 8 Department of Hepato–Pancreato–Biliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, China. 9 Department of Hepato–Pancreato–Biliary Surgery, Shandong Provincial Hospital, Shandong 250000, China. 10 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. 11 Department of Hepatobiliary and Pancreatic Surgery, Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China. -
Annual Report 2020 03 Corporate Information
Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms. -
Engineered Interferon Alpha Effectively Improves Clinical Outcomes of COVID-19 Patients
Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients Chuan Li Department of Thoracic Surgery, West China Hospital, Sichuan University Fengming Luo Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chengwu Liu Department of Thoracic Surgery, West China Hospital, Sichuan University Nian Xiong Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Zhihua Xu Department of Critical Care Medicine, Mianyang Central Hospital Wei Zhang Department of Respiratory and Critical Care Medicine, First aliated hospital, the Second Military Medical University Ming Yang Department of Respiratory Medicine, The Public Health Clinical Center of Chengdu Ye Wang Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Dan Liu Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chao Yu Department of Respiratory and Critical Care Medicine, Naval Hospital of Eastern Theater of PLA Jia Zeng Department of Aviation Disease, Naval medical center of PLA, the Second Military Medical University Li Zhang Department of Respiratory Disease, Wuhan Red Cross Hospital Duo Li Department of Respiratory Disease, The Aliated Hospital of Southwest Medical University Yanbin Liu Center of Infectious Diseases, West China Hospital, Sichuan University Mei Feng Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Ruoyang Liu Page 1/21 Department -
Social Media and China's Virus Outbreak
Volume 18 | Issue 14 | Number 6 | Article ID 5418 | Jul 15, 2020 The Asia-Pacific Journal | Japan Focus Social Media and China's Virus Outbreak Anonymous China rules the world” (2009). In an interview Abstract: In the early stage of the coronavirus with the state media CCTV, Jacques praised the outbreak in China, social media were bursting Chinese government’s crisis management with anger and desperation. Many pleaded for capacity in the wake of the pandemic, saying medical help, called for public attention to the that this, “can be a historic moment where unattended and asked for accountability for people come to see what the strengths of the local officials who failed to respond to the Chinese system are.” (Tuwen Ouni 2020) public health crisis in time. But with the epicenter shifting to Europe and NorthThis marked a dramatic turnaround from the America, a series of social media tactics, early stages of the pandemic when there was highlighting China’s successful containment speculation about whether the Chinese efforts, while disparaging foreign countries’ government’s legitimacy might be undermined responses, and spinning the origin of the by the pandemic. Public opinion in China on the coronavirus outbreak, facilitated a nationalist government’s handling of the crisis has also takeover of social media sites in China. experienced a rollercoaster ride, dipping to the bottom in early February and gradually recovering as the pandemic was contained. The state emerged from the crisis stronger than How China rewrites the narrative of the ever, trumpeting that it had led the Chinese coronavirus pandemic on social media people to victory in the war against COVID-19. -
Northeast Ohio Medical University
NORTHEAST OHIO MEDICAL UNIVERSITY DEPARTMENT OF ANATOMY & NEUROBIOLOGY Presents Synapses, muscular dystrophy and schizophrenia By Lin Mei, Ph.D. Chairman & Professor Department of Neurosciences School of Medicine Case Western Reserve University Director Cleveland Brain Health Initiative Thursday, January 10, 2019 4:00 p.m. F-118 For further information, please call (330) 325-6293 or (330) 325-6636 Page 1 of 37 Lin Mei Curriculum Vitae Department of Neurosciences School of Medicine Case Western Reserve University 10900 Euclid Ave. Cleveland, OH 44106-4975 Office Phone: 216-368-4928 Email: [email protected] Education: Diploma of Medicine, 1982, Jiangxi Medical College, Nanchang, China M.S. (Neuropharmacology), 1985, Institute of Pharmacology & Toxicology, Beijing, China. Advisor: Professor Jin-Chu Yan PhD (Pharmacology and Toxicology), 1989, University of Arizona, Tucson, Arizona. Advisors: Professors Henry I. Yamamura and William Roeske Appointments: 1981-1982, Intern, First Affiliated Hospital, Jiangxi Medical College, Nanchang, China 1989-1994, Postdoctoral Fellow/Research Associate, HHMI, Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland. Advisor: Professor Richard Huganir 1994-1999, Assistant Professor, Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 1999-2002, Assistant Professor, Neurobiology, Pathology, and Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama 2002-2004, Associate Professor, Neurobiology, -
Abstract Submission/Modification Form
Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study Yuqin Song, MD, PhD,1 Quanli Gao, MD,2 Huilai Zhang, PhD,3 Lei Fan, MD, PhD,4 Jianfeng Zhou, PhD,5 Dehui Zou, MD,6 Wei Li, MD,7 Haiyan Yang, PhD,8 Ting Liu, MD, PhD,9 Quanshun Wang, MD, PhD,10 Fangfang Lv, MD,11 Yu Yang, MD,12 Haiyi Guo, MD,13 Liudi Yang, MD,13 Rebecca Elstrom, 13 13 13 13 1 MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, and Jun Zhu, MD, PhD 1Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China 2Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China 3Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China 4Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China 5Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China 6State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 7Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China 8Department of Oncology, Zhejiang -
Dosimetric and Biological Comparison of Treatment Plans Between LINAC and Robot Systems in Stereotactic Body Radiation Therapy for Localized Prostate Cancer
Dosimetric and biological comparison of treatment plans between LINAC and robot systems in stereotactic body radiation therapy for localized prostate cancer Zhitao Dai National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Lian Zhu Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Tingting Cao ongji hospital, Tongji Medical college, Huazhong University of Science and Technology,Wuhan 430030, China. Aihua Wang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Xueling Guo Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Yongming Liu Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Yayun Zhuang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Peiying Yang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China. Ning Li National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Huojun Zhang ( [email protected] ) Department of Radiation Oncology, Changhai Hospital aliated to Navy Medical University, Shanghai, China. Zuolin Xiang Department of Radiation Oncology, Shanghai East Hospital, Tongji University, Shanghai, China.